Association between XRCC1 Arg399Gln polymorphism and glioma risk in a Chinese population: a case-control study.

Aim: In China, the incidence rates of glioma tend to be increased, however, the genetic contribution to its etiology is not well-understood. The aim of this study is to evaluate the association of XRCC1 Arg399Gln polymorphism with glioma risk in a Chinese population. Materials and methods: We conducted a case-control study on 387 patients with glioma and 400 cancer-free controls between 2004 and 2014. Peripheral blood samples of both groups were processed for DNA extraction and genotyping of the XRCC1 Arg399Gln polymorphism using PCR-RFLP. Comparison of the distribution of Arg399Gln genotypes in the study groups was performed by means of 2-sided contingency tables using the χ2 test. Hazard ratios (HRs) were estimated by Cox proportional hazard regression model. Results: When the AA genotype was used as the reference group, the GG genotype was associated with significantly increased risk for glioma (adjusted OR = 3.18, 95% CI = 1.38-3.88; P = 0.017). Under the dominant model of inheritance, the AG + GG genotype was associated with significantly increased risk for glioma (adjusted OR =2.33, 95% CI = 1.12-5.81; P = 0.023). When the A allele was used as the reference group, the G allele was associated with increased glioma risk (adjusted OR, 2.44, 95% CI, 1.76-4.18; P = 0.003). Conclusion: Our data suggests that XRCC1 Arg399Gln polymorphism contribute to increased risk of glioma, which may be susceptibility biomarkers for glioma.